Artificial intelligence augmented home sleep apnea testing device study (AISAP study)

• Published in: PloS one Vol. 19; no. 5; p. e0303076
• Main Authors: Sharma, Sunil, Olgers, Kassandra, Knollinger, Scott, Somisetty, Saivenkat, Seol, Calvin, Yanamala, Naveena
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 17.05.2024; Public Library of Science (PLoS)
• Subjects: Accuracy; Adult; Aged; Algorithms; Apnea; Artificial Intelligence; Biology and Life Sciences; Biomarkers; Cardiovascular disease; Chronic obstructive pulmonary disease; Classification; Comorbidity; Computer and Information Sciences; Desaturation; Engineering and Technology; Female; Heart failure; Humans; Hypertension; Male; Medicaid; Medical research; Medicine and Health Sciences; Medicine, Experimental; Middle Aged; Physical Sciences; Polysomnography - instrumentation; Polysomnography - methods; Prospective Studies; Pulse oximetry; Research and Analysis Methods; Sleep apnea; Sleep apnea syndromes; Sleep Apnea Syndromes - diagnosis; Sleep Apnea Syndromes - physiopathology; Sleep disorders; Statistical analysis; Type 2 diabetes
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0303076

This study aimed to prospectively validate the performance of an artificially augmented home sleep apnea testing device (WVU-device) and its patented technology. The WVU-device, utilizing patent pending (US 20210001122A) technology and an algorithm derived from cardio-pulmonary physiological parameters, comorbidities, and anthropological information was prospectively compared with a commercially available and Center for Medicare and Medicaid Services (CMS) approved home sleep apnea testing (HSAT) device. The WVU-device and the HSAT device were applied on separate hands of the patient during a single night study. The oxygen desaturation index (ODI) obtained from the WVU-device was compared to the respiratory event index (REI) derived from the HSAT device. A total of 78 consecutive patients were included in the prospective study. Of the 78 patients, 38 (48%) were women and 9 (12%) had a Fitzpatrick score of 3 or higher. The ODI obtained from the WVU-device corelated well with the HSAT device, and no significant bias was observed in the Bland-Altman curve. The accuracy for ODI > = 5 and REI > = 5 was 87%, for ODI> = 15 and REI > = 15 was 89% and for ODI> = 30 and REI of > = 30 was 95%. The sensitivity and specificity for these ODI /REI cut-offs were 0.92 and 0.78, 0.91 and 0.86, and 0.94 and 0.95, respectively. The WVU-device demonstrated good accuracy in predicting REI when compared to an approved HSAT device, even in patients with darker skin tones.